Quoi de neuf sur les troubles fonctionnels intestinaux depuis la fin du dernier millénaire ?

Irritable bowel syndrome: what’s up since the end of the last millennium?

Résumé

Les troubles fonctionnels intestinaux (TFI) sont fréquents et responsables de coûts directs et indirects importants. Durant la dernière décennie, de nombreuses avancées physiopathologiques ont été réalisées. En particulier le rôle d’une micro-inflammation, ainsi que la fonction et les dysfonctions du microbiote ont été mis en avant. Cependant, ces avancées n’ont pas permis d’isoler un ou plusieurs biomarqueurs qui permettraient un diagnostic biologique des TFI. Sur le plan thérapeutique, la première partie de la décennie a été marquée par l’échec de nouvelles molécules, liées à des effets secondaires graves. De nouvelles molécules sont en train d’apparaître. Le rôle des régimes, comme le régime sans gluten ou le régime pauvre en FODMAPs, se précise.

Abstract

IBS is frequent and induces important direct and indirect costs. During the last decade, several pathophysiological progresses have been reported. Particularly, the role of a low grade inflamation and the function, and dysfunction, of the microbiota have been put forward. However, these results did not allow to isolate one or several biomarkers which could allow a positive diagnosis of IBS. Concerning the treatment, during the first part of the decade different new drugs have been developped and launched but rapidly withdrawn due to severe side effects. New molecules are under development. The role of dietary conselling, gluten free diet or low FODMAPs diet, is being more precise.

This is a preview of subscription content, access via your institution.

Références

  1. 1.

    Sandler RS, Everhart JE, Donowitz M, et al (2002) The burden of selected digestive diseases in the United States. Gastroenterology 122:1500–11

    Article  PubMed  Google Scholar 

  2. 2.

    Longstreth GF, Thompson WG, Chey WD, et al (2006) Functional bowel disorders. Gastroenterology 130:1480–91

    Article  PubMed  Google Scholar 

  3. 3.

    Coffin B, Bouhassira D, Sabate JM, et al (2004) Alteration of the spinal modulation of nociceptive processing in patients with irritable bowel syndrome. Gut 53:1465–70

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. 4.

    Mayer EA, Naliboff BD, Craig AD (2006) Neuroimaging of the brain-gut axis: from basic understanding to treatment of functional GI disorders. Gastroenterology 131:1925–42

    Article  PubMed  Google Scholar 

  5. 5.

    Marshall JK, Thabane M, Garg AX, et al (2006) Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 131:445–50

    Article  PubMed  Google Scholar 

  6. 6.

    Liebregts T, Adam B, Bredack C, et al (2007) Immune activation in patients with irritable bowel syndrome. Gastroenterology 132:913–20

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Hughes PA, Harrington AM, Castro J, et al (2013) Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes. Gut 62:1456–65

    Article  CAS  PubMed  Google Scholar 

  8. 8.

    Matricon J, Meleine M, Gelot A, et al (2012) Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 36:1009–31

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Piche T, Barbara G, Aubert P, et al (2009) Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 58:196–201

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Ford AC, Spiegel BM, Talley NJ, Moayyedi P (2009) Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 7:1279–86

    Article  PubMed  Google Scholar 

  11. 11.

    Jalanka-Tuovinen J, Salojarvi J, Salonen A, et al (2014) Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 63:1737–45

    Article  PubMed  Google Scholar 

  12. 12.

    Mayer EA, Savidge T, Shulman RJ (2014) Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 146:1500–12

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. 13.

    Gecse K, Roka R, Ferrier L, et al (2008) Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 57:591–9

    Article  CAS  PubMed  Google Scholar 

  14. 14.

    Duboc H, Rainteau D, Rajca S, et al (2012) Increase in fecal primary bile acids and dysbiosis in patients with diarrheapredominant irritable bowel syndrome. Neurogastroenterol Motil 24:513–7

    Article  CAS  PubMed  Google Scholar 

  15. 15.

    Corsetti M, Van Oudenhove L, Tack J (2014) The quest for biomarkers in IBS-where should it lead us? Neurogastroenterol Motil 26:1669–76

    Article  CAS  PubMed  Google Scholar 

  16. 16.

    Sanders DS, Carter MJ, Hurlstone DP, et al (2001) Association of adult coeliac disease with irritable bowel syndrome: a casecontrol study in patients fulfilling ROME II criteria referred to secondary care. Lancet 358:1504–8

    Article  CAS  PubMed  Google Scholar 

  17. 17.

    Vazquez-Roque MI, Camilleri M, Smyrk T, et al (2013) A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology 144:903–11

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. 18.

    Murray K, Wilkinson-Smith V, Hoad C, et al (2014) Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol 109:110–9

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. 19.

    Halmos EP, Power VA, Shepherd SJ, et al (2014) A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 146:67–75

    Article  CAS  PubMed  Google Scholar 

  20. 20.

    Chassany O, Bonaz B, Bruley D, et al (2007) Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/trimethylphloroglucinol. A randomized, double-blind, placebocontrolled study. Aliment Pharmacol Ther 25:1115–23

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. 21.

    Wittmann T, Paradowski L, Ducrotte P, et al (2010) Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome—a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 31:615–24

    Article  CAS  PubMed  Google Scholar 

  22. 22.

    Ford AC, Brandt LJ, Young C, et al (2009) Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 104:1831–43

    Article  CAS  PubMed  Google Scholar 

  23. 23.

    Atluri DK, Chandar AK, Bharucha AE, Falck-Ytter Y (2014) Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis. Neurogastroenterol Motil 26:499–509

    Article  CAS  PubMed  Google Scholar 

  24. 24.

    Ford AC, Quigley EM, Lacy BE, et al (2014) Effect of antide-pressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 109:1350–65

    Article  CAS  PubMed  Google Scholar 

  25. 25.

    Houghton LA, Fell C, Whorwell PJ, et al (2007) Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 56:1218–25

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. 26.

    Moayyedi P, Ford AC, Talley NJ, et al (2010) The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59:325–32

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to B. Coffin.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Coffin, B. Quoi de neuf sur les troubles fonctionnels intestinaux depuis la fin du dernier millénaire ?. Colon Rectum 9, 8–12 (2015). https://doi.org/10.1007/s11725-015-0560-4

Download citation

Mots clés

  • Troubles fonctionnels intestinaux
  • Inflammation
  • Microbiote
  • Dysbiose
  • Traitement

Keywords

  • Irritable bowel syndrome
  • Inflammation
  • Microbiota
  • Dysbiosis
  • Treatment